{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:12:13Z","timestamp":1780467133819,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40744-016-0047-x","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T06:14:18Z","timestamp":1477980858000},"page":"271-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study"],"prefix":"10.1007","volume":"3","author":[{"given":"Andreas","family":"Schwarting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann O.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Specker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Cholmakow-Bodechtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker B.","family":"Koscielny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Carnarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"issue":"12","key":"47_CR1","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","volume":"50","author":"FA Houssiau","year":"2004","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934\u201340.","journal-title":"Arthritis Rheum"},{"issue":"21","key":"47_CR2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219\u201328.","journal-title":"N Engl J Med"},{"issue":"(6 Pt 2)","key":"47_CR3","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.lpm.2014.03.001","volume":"43","author":"PMK Lutalo","year":"2014","unstructured":"Lutalo PMK, Jordan N, D\u2019Cruz DP. Which dose of steroids and which cytotoxics for severe lupus? Presse Med. 2014;(6 Pt 2):e157\u201365.","journal-title":"Presse Med"},{"key":"47_CR4","doi-asserted-by":"crossref","unstructured":"N\u00f8rgaard JC, Stengaard-Pedersen K, N\u00f8rgaard M, de Thurah A. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. Lupus. 2015;24(3):299\u2013306.","DOI":"10.1177\/0961203314555351"},{"issue":"10","key":"47_CR5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/0961203314532699","volume":"23","author":"M Petri","year":"2014","unstructured":"Petri M, Bechtel B, Dennis G, et al. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. Lupus. 2014;23(10):1006\u201313.","journal-title":"Lupus"},{"issue":"8","key":"47_CR6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","volume":"53","author":"I Ruiz-Arruza","year":"2014","unstructured":"Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatol (Oxford). 2014;53(8):1470\u20136.","journal-title":"Rheumatol (Oxford)"},{"issue":"6","key":"47_CR7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF Vollenhoven Van","year":"2014","unstructured":"Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"47_CR8","first-page":"442","volume":"69","author":"B Brugos","year":"2014","unstructured":"Brugos B, Sebestyen L, Tarr T, Vincze Z. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Pharm. 2014;69(6):442\u20134.","journal-title":"Pharm"},{"issue":"1","key":"47_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrneph.2014.215","volume":"11","author":"TM Chan","year":"2015","unstructured":"Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015;11(1):46\u201361.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"47_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1586\/1744666X.2015.994508","volume":"11","author":"A Leone","year":"2015","unstructured":"Leone A, Sciascia S, Kamal A, Khamashta M. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol. 2015;11(1):109\u201316.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"47_CR11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2014.08.020","volume":"13","author":"A Kamal","year":"2014","unstructured":"Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13(11):1094\u2013101.","journal-title":"Autoimmun Rev"},{"issue":"2\u20133","key":"47_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12026-014-8565-5","volume":"60","author":"C Selmi","year":"2014","unstructured":"Selmi C, Generali E, Massarotti M, Bianchi G, Scir\u00e9 CA. New treatments for inflammatory rheumatic disease. Immunol Res. 2014;60(2\u20133):277\u201388.","journal-title":"Immunol Res"},{"key":"47_CR13","unstructured":"EMA. Benlysta-European public assessment report (EPAR) Product Information\u2014EMEA\/H\/C\/002015-IB\/0030\/G. 2014.. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002015\/WC500110150.pdf . Accessed 15 Dec 2016."},{"issue":"12","key":"47_CR14","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"47_CR15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"8","key":"47_CR16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF Vollenhoven Van","year":"2012","unstructured":"Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"47_CR17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/0961203313476154","volume":"22","author":"I Parodis","year":"2013","unstructured":"Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus. 2013;22(4):372\u201380.","journal-title":"Lupus"},{"issue":"3","key":"47_CR18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.rdc.2014.04.007","volume":"40","author":"AD Askanase","year":"2014","unstructured":"Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin North Am. 2014;40(3):507\u201317.","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"47_CR19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1517\/14712598.2014.959924","volume":"14","author":"PMK Lutalo","year":"2014","unstructured":"Lutalo PMK, D\u2019Cruz DP. Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther. 2014;14(11):1701\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"47_CR20","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253\u201365.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"47_CR21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","volume":"119","author":"MP Cancro","year":"2009","unstructured":"Cancro MP, D\u2019Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Investig. 2009;119(5):1066\u201373.","journal-title":"J Clin Investig"},{"issue":"7","key":"47_CR22","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328\u201337.","journal-title":"Arthritis Rheum"},{"key":"47_CR23","doi-asserted-by":"publisher","first-page":"e000118","DOI":"10.1136\/lupus-2015-000118","volume":"3","author":"CE Collins","year":"2016","unstructured":"Collins CE, Dall\u2019Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118. doi: 10.1136\/lupus-2015-000118 .","journal-title":"Lupus Sci Med"},{"issue":"Suppl 11","key":"47_CR24","first-page":"S291","volume":"66","author":"J Cortes","year":"2014","unstructured":"Cortes J, Andreu JL, Calvo-Alen J, et al. Evolution of patients with systemic lupus erythematous treated with belimumab in clinical practice settings. Arthritis Rheumatol. 2014;66(Suppl 11):S291.","journal-title":"Arthritis Rheumatol"},{"issue":"4 Suppl 78","key":"47_CR25","first-page":"S82","volume":"31","author":"M Mosca","year":"2013","unstructured":"Mosca M, van Vollenhoven R. New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S82\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"47_CR26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195\u2013205.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"47_CR27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.autrev.2013.11.007","volume":"13","author":"R Cervera","year":"2014","unstructured":"Cervera R, Doria A, Amoura Z, et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev. 2014;13(6):621\u20139.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"47_CR28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/BOR.0000000000000085","volume":"26","author":"V Rao","year":"2014","unstructured":"Rao V, Gordon C. Advances in the assessment of lupus disease activity and damage. Curr Opin Rheumatol. 2014;26(5):510\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"47_CR29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143\u201351.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"47_CR30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","volume":"51","author":"G Ruiz-Irastorza","year":"2012","unstructured":"Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatol (Oxford). 2012;51(7):1145\u201353.","journal-title":"Rheumatol (Oxford)"},{"issue":"2","key":"47_CR31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.amjmed.2008.09.030","volume":"122","author":"SL Silverman","year":"2009","unstructured":"Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114\u201320.","journal-title":"Am J Med"},{"issue":"2","key":"47_CR32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/0961203312469259","volume":"22","author":"DJ Wallace","year":"2013","unstructured":"Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144\u201354.","journal-title":"Lupus"},{"issue":"Suppl 2","key":"47_CR33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/annrheumdis-2014-eular.6149","volume":"73","author":"AD Askanase","year":"2014","unstructured":"Askanase AD. Clinical response to belimumab in academic clincal practices. Ann Rheum Dis. 2014;73(Suppl 2):521\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"47_CR34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/annrheumdis-2014-eular.5447","volume":"73","author":"P Brito Zeron","year":"2014","unstructured":"Brito Zeron P, Caminal-Montero L, Chamorro A, et al. Blocking the human B lymphocyte stimulator molecule (BLyS) using a monoclonal antibody (belimumab) in Systemic lupus erythematosus: first results in real-life spanish patients with refractory disease (biogeas-Semi Registry). Ann Rheum Dis. 2014;73(Suppl 2):985.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"47_CR35","first-page":"1070","volume":"65","author":"X Ke","year":"2013","unstructured":"Ke X, Patel J, Kan H, Eisenberg DF, Oglesby A. Characteristics and medication use patterns among belimumab users in a commercially insured population with systemic lupus erythematosus. Arthritis Rheum. 2013;65(Suppl 10):1070.","journal-title":"Arthritis Rheum"},{"key":"47_CR36","unstructured":"Iaccarino L, Bettio S, Ghirardello A, et al. Preliminary data on the efficacy of belimumab in the \u201creal-Life\u201d: a single centre experience. Proceedings of the 9th international congress on autoimmunity; 2014 26\u201330 March; Nice, France."},{"issue":"Suppl 2","key":"47_CR37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-eular.2880","volume":"73","author":"M Majdan","year":"2014","unstructured":"Majdan M, Kucharz EJ, Jeka S, Sierakowski S, Leszczynski P, Tlustochowicz W, et al. Early clinical experiences with belimumab in Polish patients with systemic lupus erythematosus. Ann Rheum Dis. 2014;73(Suppl 2):970.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-016-0047-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:57:35Z","timestamp":1749682655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40744-016-0047-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1007\/s40744-016-0047-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,1]]}}}